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Myotonic dystrophy (DM), the most common form of muscular dystrophy in adults, is a clinically and genetically
heterogeneous neuromuscular disorder. DM is characterized by autosomal dominant inheritance, muscular dystrophy,
myotonia, and multisystem involvement. Type 1 DM (DM1) is caused by a (CTG)n expansion in the 3
′ untranslated
region of DMPK in 19q13.3. Multiple families, predominantly of German descent and with clinically variable pre-
sentation that included proximal myotonic myopathy (PROMM) and type 2 DM (DM2) but without the DM1
mutation, showed linkage to the 3q21 region and were recently shown to segregate a (CCTG)n expansion mutation
in intron 1 of ZNF9. Here, we present linkage to 3q21 and mutational confirmation in 17 kindreds of European
origin with PROMM and proximal myotonic dystrophy, from geographically distinct populations. All patients have
the DM2 (CCTG)n expansion. To study the evolution of this mutation, we constructed a comprehensive physical map
of the DM2 region around ZNF9. High-resolution haplotype analysis of disease chromosomes with five microsatellite
and 22 single-nucleotide polymorphism markers around the DM2 mutation identified extensive linkage disequilibrium
and a single shared haplotype of at least 132 kb among patients from the different populations. With the exception
of the (CCTG)n expansion, the available markers indicate that the DM2 haplotype is identical to the most common
haplotype in normal individuals. This situation is reminiscent of that seen in DM1. Taken together, these data suggest
a single founding mutation in DM2 patients of European origin. We estimate the age of the founding haplotype and
of the DM2 (CCTG) expansion mutation to be ∼200–540 generations.
Introduction
Myotonic dystrophy (DM) is the most common muscular
dystrophy in adults, with an incidence for type 1 DM
(DM1 [MIM 160900]) of ∼1/8,000 individuals in western
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European and North American populations (Harper
2001). DM is a clinically and genetically heterogeneous
neuromuscular disorder characterized by autosomal dom-
inant inheritance, muscular dystrophy, myotonia, and
multisystem involvement (International Myotonic Dys-
trophy Consortium 2000; Harper 2001; Mankodi and
Thornton 2002). DM1 is caused by a (CTG)n expansion
in the 3′ UTR of the DM protein kinase gene (DMPK) in
19q13.3. Clinically distinct forms not associated with the
DM1 (CTG)n expansion and unlinked to 19q13.3 have
been described (Abbruzzese et al. 1996), including prox-
imal myotonic myopathy (PROMM [MIM 600109])
(Ricker et al. 1994, 1995; Thornton et al. 1994; Meola
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et al. 1996; Phillips et al. 1998; Newman et al. 1999;
Kohler et al. 2000; Kress et al. 2000; Wieser et al. 2000;
Bassez et al. 2001), proximal myotonic dystrophy (PDM)
(Udd et al. 1997), and type 2 DM (DM2 [MIM 602668])
(Day et al. 1999), which are characterized by either pre-
dominantly proximal (PROMM and PDM) or distal and
proximal (DM2) muscle involvement (Moxley et al.
1998). The mutation underlying DM2 and a subset of
PROMM was mapped to 3q21.3 (Ranum et al. 1998;
Ricker et al. 1999) and was recently identified as an un-
stable (CCTG)n expansion in intron 1 of ZNF9 (Liquori
et al. 2001). Affected families were predominantly of
German or Polish origin (Day et al. 2003).
Similar to DM1 (Ashizawa and Epstein 1991), DM2
and PROMM appear to be more prevalent in popula-
tions of European descent and, to date, have not been
reported in other populations (Moxley et al. 2002). In
DM1, there is striking linkage disequilibrium (LD)
around the (CTG)n expansion (Imbert et al. 1993; Ne-
ville et al. 1994; Yamagata et al. 1996). With the ex-
ception of one sub-Saharan kindred (Krahe et al. 1995),
a single haplotype within and flanking DMPK has been
shown to be in complete LD with DM1. This has been
interpreted as indicating that either predisposition for
(CTG)n instability resulted from a founder effect, which
occurred only once or a few times in human evolution,
or elements within the disease haplotype predispose the
(CTG)n repeat to instability (Mahadevan et al. 1993;
Neville et al. 1994).
The phenotypic similarities between patients with
DM2 and PROMM, who have linkage to 3q21 and the
DM2 (CCTG)n expansion, and patients with other re-
lated myotonic myopathies raised the possibility of a
similar mutation in kindreds initially classified as af-
fected with a clinically distinct phenotype (Moxley et
al. 1998). Moreover, we reasoned that kindreds with
DM2 representing a greater breadth of geographic or-
igin would be needed to rule out linkage heterogeneity
and to provide greater detail on a possible ancestral
haplotype. Here, we present evidence of linkage to 3q21
and mutational verification of the DM2 (CCTG)n ex-
pansion in 17 kindreds with PROMM and PDM from
geographically separate populations of European origin.
High-resolution haplotype analysis of disease chromo-
somes around the (CCTG)n expansion identified exten-
sive LD and a single shared disease haplotype in patients
with DM2 of European descent, suggesting a founder
effect similar to that seen for the (CTG)n expansion
mutation in DM1.
Subjects and Methods
Subjects and Kindreds
Enrollment of participants for this study was ap-
proved by the respective institutional review boards. Par-
ticipants were recruited by their attending physicians.
After obtaining informed consent, blood was drawn and
DNA prepared using GenePure (Gentra). For clinical
diagnosis, the criteria of the International Working
Group on PROMM and Other Proximal Myotonic Syn-
dromes were used (Moxley et al. 1998). Deceased family
members were considered affected on the basis of his-
tory. We ascertained 17 unrelated pedigrees from Ger-
many (4), Finland (3), Italy (3), the United States (2),
France (2), Spain (1), Switzerland (1) and the United
Kingdom (1) with similar clinical phenotypes, some of
which were previously described (Meola et al. 1996; Udd
et al. 1997; Phillips et al. 1998; Kohler et al. 2000; Kress
et al. 2000; Wieser et al. 2000; Bassez et al. 2001). The
DM1 (CTG)n triplet expansion was ruled out in all pa-
tients (Brook et al. 1992).
Linkage Analysis
Linkage analysis was performed using FASTLINK
(Schaffer 1996), GENEHUNTER (Kruglyak et al. 1996),
and SIMPLE (Irwin et al. 1994). Age-dependent pene-
trance classes were designated for at-risk unaffected in-
dividuals on the basis of the combined age-at-onset pro-
file for the respective kindreds. A phenocopy rate of
0.0002 was based on the incidence of myotonic dis-
charges in the general population (1/5,000).
Genetic and Physical Map of the DM2 Region
Initially, 27 microsatellite markers (23 from the Marsh-
field map and 4 novel markers derived from BAC se-
quences) flanking the DM2 locus and spanning ∼11 Mb
(10.5 cM on the sex-averaged map) were genotyped in
families with DM2 (fig. 1A). Novel markers are described
in table A (online only).
BAC clones containing sequences from the ZNF9 re-
gion were identified using the UCSC Genome Browser
(April 2002, June 2002, and November 2002 builds).
ZNF9 is on BACs RP11-814L21 (GenBank accession
number AC022944) and RP11-309B5 (GenBank acces-
sion number AC135587). On the centromeric side,
814L21 overlaps RP11-723O4 (GenBank accession
number AC112484) and RP11-434H6 (GenBank ac-
cession number AC108673). On the telomeric side, there
is a gap of indeterminate size before the next contig
(GenBank accession number NT_006025). The approx-
imate size of the gap between 814L21 and RPC1-
3_436B3 was determined by fiber-FISH (see below). The
BAC contig map is shown in figure 1B.
Using the Sequencher program (GeneCodes), we as-
sembled the sequences of the four BACs with each other
and divided 814L21 into four bins on the basis of over-
lap (fig. 5). Additional pieces of 309B5 totaling ∼30 kb
do not overlap the other clones and are assumed to be
telomeric to ZNF9. As of the November 2002 build,
exact sizes can be calculated for bins I–III. The estimated
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Figure 1 Physical and genetic map of the DM2 region in 3q21. A, Locations of the 27 microsatellite markers used. Marker order was
determined initially through use of the deCODE map (Kong et al. 2002) and then was refined using physical locations and by minimizing
recombinations in the families tested. Locations of recombinations observed are indicated by arrowheads. B, BAC clones used to map markers
close to ZNF9.
size for 309B5 was based on unfinished sequence. Be-
cause some of the published sequence of 814L21 appears
to be derived from chromosome 5, we estimated the size
of 814L21 as the minimum size determined by overlap
with the other BACs. All five exons of ZNF9 are found
within bin IV on two contigs totaling 19.8 kb, with
ZNF9 occupying a minimum of 13 kb. Exons 1 and 2
of ZNF9 are separated by a large intron that is reported
to be 120 kb (Liquori et al. 2001), although only 11.7
kb could be accounted for in this assembly. The re-
maining sequence in bin IV must be located either within
this large intron or telomeric to the gene. Figure 5 shows
the remaining four contigs of bin IV as being located
within intron 1, resulting in a maximum size for ZNF9
of 44 kb.
Physical Mapping of Genomic Clones by FISH
Metaphase FISH was used to verify that 814L21 was
not chimeric, and fiber-FISH was used to estimate the
size of the gap telomeric to ZNF9 (fig. 3). Metaphase
chromosomes and extended DNA fibers were prepared
from peripheral blood lymphocytes of a healthy indi-
vidual (Heiskanen et al. 1994; Sallinen et al. 2001).
BACs 814L21 and 529F4 and PAC 436B3 were used as
hybridization probes (fig. 3C). The clones were obtained
from the BACPAC Resource Center (Children’s Hospital
Oakland Research Institute) and were grown by stan-
dard methods; DNA was extracted using the Qiagen
Large Construct Kit. Probes for FISH were labeled with
either biotin-16-dUTP or digoxigenin-11-dUTP (Roche
Diagnostics), by nick translation using standard proto-
cols. FISH and the analysis of hybridization signals were
performed as described elsewhere (Sallinen et al. 2001).
Identification of Microsatellite Markers near ZNF9
We interrogated the sequence of 814L21 for micro-
satellite repeat sequences. In addition to the (GT)n repeat
that is directly adjacent to the DM2 (CCTG)n expansion
in ZNF9, we identified two microsatellites, 814L21-GT1
(CL3N59 [Liquori et al. 2001]) and 814L21-GT2 (fig.
5). Proximal to ZNF9 on 221E20, we identified a (GT)n
repeat, 221E20-GT1 (CL3N99 [Liquori et al. (2001]).
Distal to ZNF9, on 436B3, we identified a complex
(AG)n/(CT)n repeat (436B3-AG1). All novel markers
were confirmed by STS-content mapping of the respec-
tive BAC DNAs. Forward primers were tagged fluores-
cently (FAM or HEX), and reverse primers had 5′ tails
(5′-GTTTCTT-3′), to facilitate nontemplated polyaden-
ylation of the PCR product (Brownstein et al. 1996).
Primer sequences for all novel microsatellite markers are
described in table A (online only).
Identification of SNPs near ZNF9
To saturate the ZNF9 region with markers, we inter-
rogated various databases (CGAP Gene Viewer Web site;
dbSNP Home Page; NCBI Reference Sequence (RefSeq)
Web site; The SNP Consortium Web site) for SNPs in
the ZNF9 region. Two coding SNPs were identified, nei-
ther of which alters an amino acid: CGAP_866183
(Gly36Gly) in exon 2 and CGAP_866189 (Asp52Asp)
in exon 3. Intragenic noncoding SNP CGAP_866187 is
in exon 2 in the 5′ UTR, and CGAP_866192 and
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CGAP_866191 are in exon 5 in the 3′ UTR. These five
SNPs are all within 2.5 kb of the DM2 repeat.
TSC873597 and TSC548022 are immediately adjacent
to exon 1, and TSC1065149 is just centromeric to
ZNF9. We selected additional SNPs that were predicted
to be within or immediately adjacent to ZNF9. In all,
we interrogated 22 SNPs, all of which were verified to
be on 814L21 by STS-content mapping and were present
in our assembly on multiple BACs. Locations of all
markers are shown in figure 5.
Genotyping of Microsatellites and SNPs
Amplification of microsatellites was performed on an
ABI 9700 thermocycler, using the Qiagen Hot Start Mas-
ter Mix. Amplification products were pooled as appro-
priate and were analyzed by capillary electrophoresis on
an ABI 3100 Genetic Analyzer. Amplification from BACs
was as above, using 2 ng of template DNA.
Most SNPs were genotyped by sequencing; all se-
quencing primers were synthesized with M13 tails (table
B [online only]). Amplification was as for microsatellites;
products were cleaned using a Qiagen 96-well vacuum
manifold. Sequencing reactions were performed using
BigDye Terminator version 3.0 chemistry under stan-
dard conditions, and products were purified by ethanol
precipitation, dehydrated in a vacuum centrifuge, and
resuspended in 20 ml formamide before capillary elec-
trophoresis on an ABI 3100 Genetic Analyzer.
Five ZNF9 intragenic SNPs were typed by pyrose-
quencing. A biotinylated universal primer was used in
the amplification, and a universal tail was used on the
appropriate primer to generate biotinylated products for
pyrosequencing (table C [online only]) (Colella et al.
2003), which was conducted according to manufac-
turer’s directions. For the intragenic SNP TSC873597,
the polymorphism alters a HaeIII restriction site and was
genotyped by HaeIII (Promega) digestion according to
the manufacturer’s suggestions and visualized on 4%
Metaphor (FMC) gels.
Genotyping of Normal and Mutant (CCTG)n Alleles
in ZNF9
Normal alleles were detected by PCR across the DM2
repeat (Liquori et al. 2001). To confirm whether indi-
viduals showing a single allele had a second expanded
allele resistant to PCR, we designed a repeat-primed PCR
(RP-PCR) assay analogous to similar assays for DM1
(Warner et al. 1996; Sermon et al. 2001) and SCA10
(Matsuura and Ashizawa 2002). Primer sequences are
shown in table D (online only). Each 15-ml amplification
reaction contained 14 ng genomic DNA, 200 pmol of
DM2-RP-F, 20 pmol of DM2-RP-R4, and 180 pmol of
the universal primer. Qiagen Hot Start Mix was used
according to the manufacturer’s directions. Cycling con-
ditions consisted of initial denaturing at 95C for 15
min; 35 cycles of 95C for 45 s, 60C for 45 s, and 72C
for 2 min; followed by a final extension step at 72C
for 7 min. Products were subjected to capillary electro-
phoresis on an ABI 3100 Genetic Analyzer, and results
were viewed using the Genotyper program.
DM2 (CCTG)n Expansion Detection by Field Inversion
Electrophoresis (FIGE)
For Southern blot detection of the DM2 (CCTG)n
expansion, 5–10 mg of high-molecular-weight genomic
DNA extracted from peripheral blood leukocytes or
lymphoblastoid cell lines by standard techniques were
digested with EcoRI (NEB). For each kindred, one par-
ent-offspring pair (when available) and one unaffected
founder or pedigree member were examined. To obtain
adequate resolution in the range of expansion, FIGE was
used. In brief, digested samples were separated by elec-
trophoresis on 1% agarose (BIO-RAD) on the FIGE
Mapper (BIO-RAD), using program 3 (180 V forward,
120 V reverse, and switch time ramp 0.12.0 s, linear
shape) for 13 h. Samples were transferred to Hybond
N blotting membranes (Amersham). Detection was
with a probe specific for the DM2 (CCTG)n expansion
(Liquori et al. 2001) in RapidHyb solution (Amersham),
using standard serial stringency washes followed by
phosphorimaging and/or autoradiography.
Selection and Preparation of Samples
To determine whether a unique haplotype segregates
with the DM2 expansion, we selected families in which
the DM2 expansion was segregating and families with
normal alleles. In all, 265 individuals were studied. From
the families with DM2, we chose 60 affected and 38
normal individuals, as well as 30 index cases. Control
families were selected from the same ethnic backgrounds
as the families with DM2 and included 126 members of
13 families and 11 unrelated individuals. Four monoal-
lelic somatic cell hybrid lines resulting from diploid-to-
haploid conversion (Yan et al. 2000), each containing
one chromosome 3 homologue from a Finnish patient
with DM2 (two normal and two DM2 lines), served as
controls. A 16-sample screening panel included the four
hybrid lines. Markers that showed at least one hetero-
zygous individual in the screening set were genotyped
on all samples.
Analysis of Data
Population allele frequencies for all markers were cal-
culated using independent normal chromosomes, both
phase-known and phase-unknown. For haplotype anal-
ysis, only phase-known independent DM2 and normal
chromosomes were used. Multipoint linkage analysis
and haplotype construction were conducted with GENE-
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HUNTER. In all, we were able to unequivocally char-
acterize 17 independent phase-known chromosomes
containing the DM2 (CCTG)n expansion and 160 phase-
known normal chromosomes.
Determination of LD
To determine LD between markers near the DM2
(CCTG)n repeat and chromosome disease status, we used
x2 contingency-table tests for each marker. A multipoint
haplotype method employed by Borrego et al. (2003) and
Cheng et al. (2003) was used, in which subhaplotypes of
all possible widths were examined for association with
disease. For each marker, the smallest nominal P value of
the x2 statistic was recorded for all haplotype windows
containing the marker. For these analyses, reconstructed
haplotypes were used, and only the 103 normal haplo-
types with no missing alleles were included. Initial sen-
sitivity analyses indicated that the multipoint results de-
pended greatly on microsatellite marker 814L21-GT1.
Therefore, analyses were also performed with that marker
excluded. Permutation tests were performed by randomly
labeling sets of 17 haplotypes as “diseased” and the re-
mainder as “normal” and then recomputing the overall
test statistic. Empirical P values for the entire set of mark-
ers were thus obtained as the proportion of 1,000 per-
mutation samples for which the permuted test statistic
was more extreme than the observed statistic. Simple mo-
ment-based estimates of core ancestral haplotype fre-
quencies and mutation age can be obtained as described
by Borrego et al. (2003). In brief, a putative core ancestral
haplotype was identified and treated as a single allele with
frequencies pdisease among disease chromosomes and pnormal
among normal chromosomes. The quantity p pexcess
simultaneously highlights the(p  p )/(1 p )disease normal normal
area of greatest LD and, at its peak, serves as a crude
estimate of the proportion of disease chromosomes de-
scended from the major mutation (de la Chapelle and
Wright 1998). A simple regression of on thelog (p )excess
genetic distance from the DM2 expansion (Borrego et al.
2003) can be used to estimate the age of the mutation,
although it is difficult to assign confidence intervals when
such moment-based approaches are used (Slatkin and
Rannala 2000). For the regional recombination rate per
megabase, we used the deCODE map (Kong et al. 2002).
To supplement the haplotype analyses and obtain interval
estimates for the mutation age, the program DMLE
(Reeve and Rannala 2002), employing Bayesian multi-
point population genetic modeling, was used to examine
the data for evidence of a founding locus, using the entire
set of 160 normal haplotypes.
Results
Linkage to 3q21 and Confirmation of DM2 (CCTG)n
Expansion
Genomewide scans for linkage were performed on
four kindreds (FIN01, I01, US01, and US02) with sets
of 400 markers at 10-cM intervals. The highest individ-
ual and cumulative LOD scores were seen for markers
in 3q21, when weakness, myotonia, and cataracts were
considered together. No other markers yielded LOD
scores exceeding those for 3q21. Thus, these kindreds
were considered to show linkage to 3q21, the same re-
gion to which DM2 had been mapped (Ranum et al.
1998).
Subsequently, 13 additional kindreds meeting our clin-
ical criteria (Moxley et al. 1998) were identified. Linkage
analysis for all 17 families, through use of the markers
shown in figure 1A, provided a peak multipoint LOD
score of 19.521 at D3S3584. Using informative cross-
overs, we further narrowed the critical region to a 2.06-
cM interval between D3S3584 and RHO (fig. 1A). Ev-
idence of allele and haplotype sharing was seen, in three
Finnish families, with markers D3S3584, 153F10-GT1,
D3S3606, D3S3607, and 571C11-AG1. When markers
derived from the BAC sequences were included, the peak
multipoint LOD score was 23.445 and haplotype shar-
ing extended to 436B3-AG1.
When checked for the DM2 (CCTG)n expansion in
ZNF9 (Liquori et al. 2001), all affected individuals
showed a single allele by PCR analysis. Affected children
presented with an apparent non-Mendelian inheritance,
indicating that PCR amplified only the allele inherited
from the unaffected parent. Segregation of the DM2
(CCTG)n mutant expansion in our kindreds was con-
firmed by Southern blot analysis. Using FIGE, we iden-
tified expansions ranging from approximately 4 kb to
27 kb, with a mean expansion size of ∼17–18 kb.
Figure 2A and B show the detection of the DM2 ex-
pansion by FIGE Southern blot analysis and a represen-
tative PROMM pedigree. Since Southern blot analysis
can fail to detect expansions (individual II:6; fig. 2B),
because of the unusual size and somatic heterogeneity
of the (CCTG)n expansion, we also developed an RP-
PCR assay to determine the presence of the mutation.
Combining PCR analysis across the DM2 repeat with
our FIGE Southern blot and/or RP-PCR analyses, we
were able to unequivocally determine the presence of a
DM2 (CCTG)n expansion in all affected individuals and
to determine the size of the expansion in most of them.
Sequence analysis of normal alleles of the DM2-as-
sociated (CCTG)n repeat showed the same complex
repeat motif (TG)20-24(TCTG)6-10(CCTG)11-16 as
reported by Liquori et al. (2001). The majority of ex-
pansion carriers showed broad smears or multiple bands
Figure 2 Molecular diagnosis of the DM2 (CCTG)n expansion mutation in an Italian family (I01) with PROMM and other selected cases.
A, FIGE Southern blot showing expanded (CCTG)n alleles at the DM2 locus. Shown beneath each lane are the PCR allele sizes across the DM2
repeat and the results (/) of the RP-PCR assay. Pedigree numbers in the lane headers refer to those shown in the pedigree (B). A and B are
haploid hybrids for the normal and mutant chromosome 3, respectively; AB is the donor patient from which the hybrid cell lines were established;
M is the size marker lane; and cases 1–3 are individual, unrelated patients. B, Pedigree of PROMM kindred I01 (Meola et al. 1996), illustrating
commonly encountered diagnostic problems and the importance of using multiple molecular diagnostic tests. Individual II:4 exemplifies a false-
positive diagnosis. He had myotonia but had two normal alleles and showed no expansion by either RP-PCR or Southern analysis (“S”). For
individual II:6, who has myotonia and muscle weakness, Southern analysis gave an unclear molecular diagnosis, whereas RP-PCR clearly
identified him as a mutation carrier. Individual IV:1 has a false-negative diagnosis. Although phenotypically normal, he has an expansion of
16.5 kb. Individual IV:3 is a true homozygote. Both RP-PCR and Southern analysis confirm the absence of the expansion, in spite of the
presence of only a single allele.
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Figure 3 Chromosomal location and physical map of the BAC and PAC clones from the ZNF9 region determined by FISH. A, RPC1-
3_436B3 was assigned to 3q21 by metaphase FISH (red). B, Ideogram of human chromosome 3. C, Mutual order of RP11-814L21, RPC1-3
436B3, and RP11-529F4, and the size of the gap in the physical map determined by fiber-FISH. Cohybridization of the three clones shows the
order RP11-814L21–RPC1-3_436B3–RP11-529F4. A schematic representation of the genomic clones is shown below the image. The approximate
size of the gap between RP11-814L21 and RPC1-3 426B3 was estimated at 227 kb (SD 59 kb).
by Southern blot analysis, indicating somatic instability.
Thus, the expansion detected in our kindreds presenting
with a highly variable clinical phenotype that was orig-
inally considered distinct from DM2 (Moxley et al.
1998) was the same type of expansion seen in DM2
(Liquori et al. 2001).
Verification of the Physical Map by STS-Content
Mapping and FISH
To study the evolution of the DM2 (CCTG)n muta-
tion, we constructed a comprehensive physical map of
the DM2 region. All markers used were confirmed to be
present on 814L21 by STS-content mapping. We also
performed FISH analysis of this clone and verified that
it contained only DNA localizing to 3q21. Chromoso-
mal location of the genomic clones 814L21, 436B3, and
529F4 was confirmed by FISH. All three clones mapped
to chromosome 3q21 (fig. 3A and 3B).
After confirming the location and excluding chimer-
ism, the clones were hybridized in different combinations
to extended DNA fibers to establish their mutual order
and the distance separating 814L21 and 436B3. Double-
color fiber-FISH experiments confirmed the order of the
clones (figs. 1B and 3C). The average gap size between
814L21 and 436B3 was determined to be 227 kb (SD
59; ).np 9
Microsatellite Allele Sharing in Patients
With microsatellites closer to the DM2 expansion
(221E20-AG1, 814l21-GT1, and 436B3-AG1), more ex-
tensive allele sharing was seen in the same three Finnish
families as before. A subregion of this haplotype cen-
tromeric to the expansion was shared by three German,
one U.S., one French, and one U.K. family (northern
haplotype). In five families (one Spanish, one French,
and three Italian) a different set of alleles was shared at
221E20-AG1 and 814L21-GT1 (southern haplotype)
(fig. 4).
Microsatellites 1350 kb from the repeat had allele
frequencies on DM2 chromosomes that were similar to
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Figure 4 Shared microsatellite marker haplotypes in families with DM2 over 5 Mb flanking the DM2 mutation. The country of origin
of samples is indicated (CH p Switzerland; D p Germany; E p Spain; F p France; FIN p Finland; I p Italy; NY p United States; UK p
United Kingdom). The 154-bp allele at 814L21-GT1 and 183-bp allele at 221E20-GT1 are seen predominantly on DM2 chromosomes of
northern European origin (Finland, Germany, United Kingdom, and France). The 148-bp and 176-bp alleles at these respective loci are seen
predominantly on DM2 chromosomes of southern European origin (Spain, Italy, and France). Alleles in common are indicated by shading.
those seen in normal individuals. Markers 814L21-GT1
(located ∼130 kb centromeric from the expansion) and
436B3-AG1 (located ∼200 kb telomeric from the ex-
pansion) showed a preponderance of just two alleles on
disease chromosomes, suggestive of disequilibrium with
the repeat expansion. Normal chromosomes had nine
alleles at 814L21-GT1. The 154-bp allele (population
frequency 9%) was seen on 9 of the 17 DM2 chro-
mosomes (53%). The 257-bp allele at marker 436B3-
AG1 seen on 6 of the 17 expansion chromosomes (35%)
was observed on only 1 of 153 normal chromosomes
(!1%).
High-Resolution SNP Mapping of DM2 Chromosomes
Figure 5 shows the results of our high-resolution
marker analysis of the DM2 region. Of the 22 SNPs
interrogated, only 6 showed variation in the testing sam-
ple set and only 2 of these had a minor allele frequency
15%. All markers used in this study were determined to
be in Hardy-Weinberg equilibrium. SNPs rs2341295 and
TSC0176095 are located 171 bases apart on the same
amplified fragment and were treated as a multiallele lo-
cus. Observed allele frequencies are shown in table E
(online only).
Because of low polymorphism, there was no difference
in allele frequencies between DM2 and normal chro-
mosomes for five of the six SNPs. However, TSC873597,
∼13–30 kb telomeric to the expansion, showed only the
“C” allele on the 17 DM2 chromosomes. The frequency
of “C” for normal chromosomes was 50%. A Fisher’s
exact test for this difference was highly significant
( ). In an unrelated group of 11 DM25Pp 3.0# 10
index cases, no instances of the AA genotype were seen,
consistent with the presence of the “C” allele on the
DM2 haplotype. Taken together, these data are consis-
tent with a single origin for the DM2 mutation occurring
on a chromosome bearing the “C” allele at TSC873597.
Characterization of Haplotypes in DM2 and Control
Families
All 17 independent DM2 chromosomes were invariant
for all markers from rs762570 to TSC873597, ∼132–
163 kb (the boxed region in fig. 5), and shared a single
haplotype identical to the most common normal hap-
lotype (fig. 6A). We observed a total of 10 different
haplotypes on 160 independent normal chromosomes.
The most common haplotype (A) was present on 46.8%.
The second most common haplotype (B) was present on
41.25% and differed from A only at TSC873597 (fig.
6A). The 10 observed haplotypes and their evolutionary
relationships to each other are shown in figure 6B. This
is reminiscent of the situation in DM1 (Imbert et al.
1993; Neville et al. 1994). Taken together, these data
suggest a single founding mutation in patients with DM2
from diverse European populations.
LD in the DM2 Region
The permutation tests to determine LD in the DM2
region were highly significant (P values !.001) whether
or not marker 814L21-GT1 was included (fig. 7). With
814L21-GT1 included, the evidence peaks ∼120 kb cen-
tromeric to the DM2 expansion. When 814L21-GT1
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Figure 6 A, Haplotypes observed across the DM2 region. Ten normal haplotypes (A–J) are shown, along with the DM2 haplotype, which
is identical to haplotype A except for the presence of the DM2 (CCTG)n expansion. B, Haplotype evolutionary network based on parsimony.
The areas of circles representing each haplotype are roughly proportional to the frequency of the haplotype being represented. Each haplotype
is one mutational step from all of the haplotypes to which it is connected by a line. Haplotypes G and H are the only two haplotypes for which
relationships are unclear. Haplotype G is either the result of a recombination or gene conversion event between the common haplotypes A and
B (indicated by X) or the result of a repeat mutation (homoplasy), in which haplotype A changed by acquiring the mutation that is diagnostic
for B or vice versa.
was removed from the analysis, a core haplotype from
rs900314 to TSC873597 (fig. 5) was apparent on 11/
17 DM2 haplotypes but on only 10/103 normal hap-
lotypes ( , Fisher’s exact test). Alleles 1486Pp 2.2# 10
and 154 of 814L21-GT1 occur almost exclusively in
disease haplotypes and occur in 10/11 of the disease
chromosomes with the putative extended core haplo-
type. These observations appear consistent with a mi-
crosatellite mutation occurring on the core haplotype
sometime later than the original mutation event. This
scenario is further supported by the fact that affected
kindreds with allele 148 versus allele 154 appear to
roughly correspond to families of southern European
versus northern European ancestry. When 814L21-GT1
is removed from the analysis, the evidence for LD is
constant across a broad interval (fig. 7). Under this hy-
pothesis, the bias in the higher curve (fig. 7) stems from
the proposed microsatellite mutation, combined with the
greater informativeness of the 814L21-GT1 microsat-
ellite marker compared with the surrounding SNP
markers.
When 814L21-GT1 was excluded, the simple mo-
ment-based procedure gave an estimate of 208 genera-
tions since the founding haplotype, accounting for a
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Figure 7 Evidence for LD with disease status for markers near the DM2 (CCTG)n expansion. The Y-axis shows nominal P values (on a
scale) for the moving-window haplotype contingency-table test. The evidence when marker 814L21-GT1 is included (unblackened circles) log10
peaks centromeric to the expansion and is much stronger than when the marker is excluded (blackened circles). Permutation-based P values
for the entire set of markers gave for both curves.P ! .001
pexcess of 60.9% of the disease haplotypes. The estimated
mutation age depended somewhat on the assumed his-
torical population growth rate, with 90% credible in-
tervals of 380–465 generations, for a growth rate of 5%
per generation, and 515–540 generations, for a growth
rate 2% per generation. Although these estimates are
higher than that provided by the moment-based ap-
proach, they are dependent on population modeling as-
sumptions. Using an average generation time of 20 years,
the estimates correspond to a mutation age range of
∼4,000–11,000 years. We view the data, when taken
together, as consistent with the DM2 mutation origi-
nating in Europe but being ancient enough to be present
in several European subpopulations.
Discussion
We studied 17 kindreds with disease that was originally
classified as PDM or PROMM on the basis of clinical
presentation and was therefore considered a distinct clin-
ical entity from DM2 (Moxley et al. 1998). Here, we show
linkage to the DM2 region in 3q21 (Ranum et al. 1998)
and confirm the presence of the DM2 (CCTG)n expansion
mutation (Liquori et al. 2001; Day et al. 2003) in all of
our patients. It has been suggested that PROMM/DM2
is predominantly a disease of German or northern Eu-
ropean origin (Day et al. 2003). Our study of patients
from diverse (southern and northern) European popula-
tions indicates that PROMM/DM2 is not limited to pa-
tients of northern European descent but is more widely
spread throughout European populations.
Since the molecular diagnosis and accurate sizing of
the DM2 expansion mutation can be difficult and un-
reliable because of the unprecedented size of the expan-
sion (Liquori et al. 2001), we developed a FIGE-based
protocol (fig. 2A) and an RP-PCR assay. Approximately
5%–10% of normal individuals have two identically
sized alleles for the polymorphic DM2 repeat; thus, PCR
across the repeat is a useful first test for DM2. With our
RP-PCR assay, homozygous normal individuals can be
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readily distinguished from mutation carriers with an ex-
panded allele resistant to standard PCR. The RP-PCR
procedure is also useful for confirmation when Southern
blot analysis is equivocal (∼20% of the time [Day et al.
2003]). Our FIGE-based Southern blot approach pro-
vides a means for reliable size determination of the repeat
beyond the resolution of standard gel electrophoresis
(120 kb). Using these methods in combination, we were
able to unequivocally identify all mutation carriers in our
sample set.
Initial analysis of shared microsatellite haplotypes in
our 17 European kindreds identified a southern and a
northern European haplotype and suggested the pos-
sibility of population-specific or regional founder effects
(fig. 4). To further study the evolution of the DM2 re-
peat, we generated a high-resolution genetic and phys-
ical map of the DM2 region (figs. 1 and 5). Further fine
mapping of disease chromosomes with the additional
microsatellite and SNP markers showed complete con-
servation of a single common haplotype shared among
all affected individuals from the 17 kindreds studied
(figs. 5 and 6A). Comparison with population-matched
unaffected individuals showed that the DM2 expansion
segregates on the most common normal haplotype (A),
with the expansion being the only difference (fig. 6A).
Interestingly, in the 200-kb region flanking the DM2
repeat, there are relatively few microsatellite markers,
and the available SNPs were not very polymorphic, sug-
gesting that this region is part of an invariant haplotype
block. This notion is further supported by the identi-
fication of only two major haplotypes (A and B), which
together account for ∼89% of all observed haplotypes.
On the basis of the highly statistically significant LD
(fig. 7) and the extent of LD observed (∼132–163 kb;
figs. 5 and 7), we estimated the age of the DM2 mu-
tation at ∼4,000–11,000 years. These data, taken to-
gether with the lack of reports for DM2 in non-Euro-
pean populations, suggest a single (or a few) founding
mutation(s) for the DM2 expansion in patients of Eu-
ropean descent after the migration out of Africa. Thus,
the situation in DM2 is similar to that seen in DM1, in
which all patients of European descent segregate the
(CTG)n expansion on a single haplotype (A). However,
the fact that the LD seen in DM1 is significantly smaller
(∼40 kb [Imbert et al. 1993; Neville et al. 1994]) and
the fact that DM1 is found in the Japanese population
(Yamagata et al. 1998) suggest that the DM2 expansion
mutation occurred more recently. The large variability
in estimated ages is not unique to the present data set
(see, for example, Slatkin and Rannala 2000), but the
evidence supports the conclusion that the mutation, al-
though not extremely ancient, may be old enough to be
widespread in European populations.
The observed LD extends for a 3–4 times greater
distance on the centromeric side of the DM2 repeat than
the telomeric side (fig. 7), whether or not the micro-
satellite marker 814L21-GT1 is included in the calcu-
lations. The apparent skewing of the LD region could
result from sampling variability or from a lower recom-
bination rate to the centromeric side. Alternatively, the
LD peak at 814L21-GT1 (when the marker is included)
might reflect an unknown cis-acting element contrib-
uting to the DM2 expansion, as has been suggested for
DM1 and other trinucleotide-repeat diseases (Brock et
al. 1999). Additional evidence for the involvement of
flanking sequences comes from the variable stability of
similar (CAG)n repeats at different disease loci (Richards
et al. 1996; Brock et al. 1999; Cleary et al. 2002) and
from transgenic mouse models of trinucleotide-repeat
instability (Gourdon et al. 1997; Monckton et al. 1997).
Although the nature of such a cis element(s) is currently
unknown, recent in vitro studies suggest that the dis-
tance of the repeat to the replication origin may be an
important factor (Cleary et al. 2002).
In conclusion, patients of non–northern European de-
scent presenting with progressive myotonic myopathy
should be examined for the DM2 (CCTG)n expansion
mutation in 3q21, if negative for the DM1 (CTG)n ex-
pansion mutation. The identification of the same genetic
mutation in patients presenting with highly varied
clinical phenotypes with predominantly or exclusively
proximal muscle involvement (PDM and PROMM), in
contrast to the distal (and proximal) muscle involve-
ment described in kindreds with DM2 (Day et al. 1999;
Ranum et al. 1998), indicates that the clinical manifes-
tations caused by the (CCTG)n expansion mutation are
more varied than initially appreciated (Moxley et al.
1998) and suggests that modifying genetic factors and
genetic background act in concert with the (CCTG)n
expansion mutation.
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